| 前收盘价格 | 0.432 |
| 成交量 | 84,360 |
| 预期市盈率 (P/E Forward) | 42.73 |
| 价格/销量 (P/S) | 0.470 |
| 股市价格/股市净资产 (P/B) | 1.43 |
| 52周波幅 |
| 营业毛利率 | -122.63% |
| 营业利益率 (TTM) | -71.54% |
| 稀释每股收益 (EPS TTM) | -0.260 |
| 季度收入增长率 (YOY) | 857.20% |
| 总债务/股东权益 (D/E MRQ) | 45.07% |
| 流动比率 (MRQ) | 0.640 |
| 营业现金流 (OCF TTM) | -33.17 M |
| 杠杆自由现金流 (LFCF TTM) | 50.39 M |
| 资产报酬率 (ROA TTM) | -28.90% |
| 股东权益报酬率 (ROE TTM) | -114.74% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Vaxart, Inc. | 混合的 | 混合的 |
AIStockmoo 评分
-1.6
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | -2.5 |
| 平均 | -1.57 |
|
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 0.88% |
| 机构持股比例 | 12.08% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Beacon Capital Management, Llc | 31 Dec 2025 | 0 |
| Custos Family Office, Llc | 31 Dec 2025 | 0 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合